MorphoSys (NASDAQ:MOR) Lowered to Hold at Zacks Investment R

MorphoSys (NASDAQ:MOR – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, […]

Related Keywords

Germany , United States , Planegg , Bayern , , Capricorn Fund Managers Ltd , Morgan Stanley , Berenberg Bank , Goldman Sachs Group Inc , Zacks Investment Research , Deutsche Bank Aktiengesellschaft , Susquehanna International Group , Alphacentric Advisors , Morphosys Company Profile Get Rating , Millennium Management , Citigroup , Get Rating , Fund Managers Ltd , Centric Advisors , Sachs Group , International Group , Sys Company Profile , Morphosys , Nasdaq Mor , Humor , Medical , Downgrade ,